Nordic Pharma Group

Mitomycin C

Laura Wild Berthier — 2010-05-01T12:58:00Z

The Nordic Group obtains the marketing rights for Mitomycin C Kyowa in Central & Eastern Europe.

The Nordic Group obtained on May 1st, 2010, the exclusive marketing rights for Mitomycin C, an antineoplastic agent from Kyowa Hakko Kirin Co. Ltd. in the Czech Republic, the Slovak Republic, Hungary, Poland, and Bulgaria, as well as Russia, the Ukraine and Georgia.

Mitomycin C Kyowa was launched in Central & Eastern European countries about 25 years ago and until now, it has been commercialized through different distributor channels.

Mitomycin C Kyowa is prescribed in the treatment of malignant neoplastic diseases, including disseminated adenocarcinoma of the stomach, pancreas and colon. However, its main use is as an instillation after resection in the treatment of non-muscle invasive bladder cancer.

The Nordic Group is a pan European, fully integrated pharmaceutical company focused on hospital products in a few, selected therapeutic areas that have significant unmet medical needs.

Nordic Pharma Italy

Laura Wild Berthier — 2010-03-01T13:38:00Z

After its creation in 2009, Nordic Pharma S.r.l. launched its new offices in Milano on March 1st, 2010.

The Nordic Group's Italy affiliate is now fully operational and prepared for further growth in the field of gynaecology and hospital therapeutic areas.

Management Team

inouit — 2009-05-12T09:27:31Z

Drs. Hans Schram - CEO and Managing Director

Drs. Schram has a Chemistry degree from Leiden University in the Netherlands and over twenty years of experience in the global Pharmaceutical industry.
Prior to joining Nordic, he spent 18 years at Ferring, where he was a member of the Executive Management team.
Prior to Ferring, he was at Ciba Geigy and at Pierre Fabre Laboratories.
Drs. Schram joined the Nordic Group as the CEO and Managing Director in 2002.

The Nordic Group
216, boulevard St. Germain
75007 Paris
France
Tel. +33 1 53 63 88 77
Fax +33 1 45 48 76 50
info@nordicpharma.com

Stéphane Altaba, PhD, Director Corporate Business Development

Dr. Altaba has an engineering degree in Agronomy, a PhD in Biotechnology and a postgraduate degree in Management from the ESCP-EAP business school. For over 10 years, he had responsibilities in R&D and Industrial Affairs in RPR, and in Business Development within Aventis and Sanofi Aventis. In his last assignment at Sanofi Aventis, he was in charge of Corporate Business Development for the Oncology franchise. Dr. Altaba joined the Nordic Group in August 2006.

The Nordic Group
216, boulevard St. Germain
75007 Paris
France
Tel. +33 1 53 63 88 77
Fax +33 1 45 48 76 50
info@nordicpharma.com

Charlotte Phelps, General Manager of Nordic Pharma UK

After an early career in research, Ms. Phelps moved to the Pharmaceutical industry in mid-80’s. Following a successful time in sales, she moved to Global Marketing, where she was responsible for a number of product ranges including the launch of a new chemical entity in Obstetrics. Ms. Phelps has experience in a wide range of therapy areas, including Cardiovascular, Mental health, Endocrinology, Critical Care, Haematology and Obstetrics.
Ms. Phelps is responsible for establishing and running the Nordic UK affiliate as of mid-2002.

Nordic Pharma UK
Abbey House
1650 Arlington Business Park
Theale, Reading RG7 4SA
United Kingdom
+44 118 929 8233
+44 118 929 8234
info@nordicpharma.co.uk

Dr. Véronique Rebours-Mory, General Manager of Nordic Pharma FR

Dr Rebours-Mory is a Pharmaceutical doctor from the University of Lyon. She started her career in the late 80’s and has since developed her skills in Sales, Marketing, Operational Clinical Development, European Project Management, International Business Development, and General Management in fully integrated Pharmaceutical companies. She also has experience in several therapeutic areas, including Neurology, Infectious Diseases, Oncology, Gynaecology, Gastroenterology, Critical Care and Rheumatology. Dr. Rebours-Mory joined the Nordic Group in 2002 to create and develop Nordic’s French affiliate.

Nordic Pharma France
10, rue René Anjolvy
94250 Gentilly
France
Tel. +33 1 72 46 72 00
Fax +33 1 72 46 72 29
info@nordicpharma.com

Günter Lützenkirchen, General Manager of Nordic DE

Dr. Lützenkirchen has a background in Chemistry and Biology with a Ph.D. in Biology from the University of Freiburg/Brsg.
He started his marketing-based career as a Product Manager with Ciba-Geigy and Sandoz. He then held various positions of increasing responsibility in Marketing and General Management with Pharmacia and Searle, Antisense Pharma, and Brand Institute Germany. His most recent position in the pharmaceutical industry was as Managing Director of the German affiliate of Biogen Idec GmbH.
Dr. Lützenkirchen joined Nordic Group on July 1^st, 2008 as the General Manager of Nordic’s German affiliate.

Nordic Pharma Germany
Fraunhoferstr.4
85737 Ismaning
Germany
Tel. +49 89 889 690 680
info@nordicpharma.de

Ivana Stivinova, M.D, General Manager of Nordic Pharma CZ

Dr. Stivinova graduated as a medical doctor. She began working in the pharmaceutical industry over 15 years ago, when she joined Glaxo as sales representative.
Dr. Stivinova then spent nearly 10 years in Ferring both as a Product Manager and as a Marketing & Sales Manager in the Czech Republic. She eventually became an International Project Specialist in Ferring in Copenhagen and later the Marketing & Sales Manager for Central and Eastern Europe (based in Vienna).
Dr. Stivinova joined the Nordic Group in 2003 to manage the challenging job of General Manager, Nordic Pharma Czech Republic, as well as to oversee all Marketing and Sales activities there and in the rest of Central and Eastern Europe.

Nordic Pharma Czech Republic
Zachova
140 000 Prague 4 - Krc
Czech Republic
Tel. +420 241 029 544
info@nordicpharma.cz

Anders Löfgren, DDS, MBA, Managing Director of Nordic Drugs

Mr. Löfgren has a double qualification as a DDS (Doctor of Dental Surgery) and as an MBA. Mr. Löfgren is also a trained Army Officer with the rank of Captain.
Mr. Löfgren counts an impressive 18 years in the Pharmaceutical Industry in various well-known companies (Ciba-Geigy, Searle, Ferring). He has broad Marketing experience both in Scandinavia and in the rest of Europe.
Mr. Löfgren was one of the first to join the Nordic Group of companies, back in 1996.

Nordic Drugs Sweden
Geijersgatan 2 A
200 61 Limhamm
Sweden
Tel. +46 40 36 66 00
info@nordicdrugs.se

Luc Sterkman, M.D., General Manager of Disphar

Dr. Sterkman studied medicine at the University of Amsterdam. After he graduated as a medical doctor, he joined the Pharmaceutical Industry, where he held various positions in Sales, Marketing, Business Development, Project Management and finally General Management.
Dr. Sterkman has worked for companies in the Innovative Pharmaceutical Industry (Pharmacia and Bayer), the Biotech Industry (IsoTis) and the CRO Industry (Kendle). He established impressive growth at some of these companies and successfully completed funding rounds and an Initial Public Offering (IsoTis).
Dr. Sterkman joined the Nordic Group through Disphar in January 2005.

Disphar International
Tolweg 15
3741 LM Baarn
The Netherlands
Tel. +31 35 5280 403
Fax. +31 35 5480 585

Kenneth Stokholm, Managing Director of QPharma

Mr. Stokholm has a technical background in chemical engineering and holds an MSc. He joined the pharmaceutical industry in Novo Nordisk in Denmark and has since held various leading positions within Supply Chain and Operations as well as Project Management.
His last assignment was establishing a pharmaceutical facility for Alpharma in Taizhou, China, where he held the position as Managing Director. The facility was built, the organisation established and developed and the site is today in operation and approved by FDA.
Mr. Stokholm joined QPharma, and the Nordic Group, in January 2009.

QPharma
Agneslundsvägen 27
20 125 Malmö
Sweden
Tel. +46 40 36 18 00
Fax +46 40 18 28 55
info@qpharma.se

Petr Janda, MD, General Manager of Prague Clinical Services

Dr. Petr Janda is a medical doctor who graduated with specialisations in Internal Medicine and Nephrology from Charles Univesity in Prague, Czech Republic. He has over 16 years of experience in clinical studies, in particular within Ciba Geigy and Ferring. In the past, he was responsible for worldwide clinical activities from phase I – IV, as well as registration and pharmacovigilance activities.
Dr. Janda has been Managing Director of Prague Clinical Services since 2004 and under his guidance Prague Clinical Services has grown into one of the most prominent independent CROs in Central & Eastern Europe. Moreover, Dr. Janda is the President of ACRO-CZ (the Czech CRO Association) and a management team member of EUCROF (the European CRO Federation).

Prague Clinical Services
Zachova 8
140 00 Prague 4 – Krc
Czech Republic
Tel. +420 241 029 551
Fax. + 420 241 442 852
info@pragclin.com

Nordic Pharma Germany

Laura Wild Berthier — 2009-01-03T15:07:00Z

The Nordic Group's German affiliate is now fully operational.

After its creation in 2008, Nordic Pharma GmbH announced the launch of its new offices in the Ismaning business park near Munich on January 1st, 2009.
The Nordic Group's German affiliate is now fully operational and prepared for further growth as a preferred partner in the speciality and hospital therapeutic areas.
Nordic Pharma Germany currently markets three innovative hospital products : Synercid(r), Siklos(r) and Hyalobarrier(r).

Contact Us

inouit — 2008-04-28T09:43:37Z

Corporate/Business Development
216 Boulevard St. Germain 75007 Paris France Tel. +33 1 53 63 88 77 Fax. +33 1 45 48 76 50 info@nordicpharma.com business.development@nordicpharma.com

Nordic Drugs

Nordic Drugs - Sweden	Nordic Drugs - Denmark
Geijersgatan 2 A 200 61 Limhamm Sweden Tel. +46 40 36 66 00 info@nordicdrugs.se	Halmtorvet 29, 1700 Copenhyagen V Denmark Tel. +45 70 20 08 40

Nordic Drugs - Norway	Nordic Drugs - Finland
Holmenveien 20 Vinderen, 0319 Oslo Norway Tel. +47 23 22 11 44	Piispansilta 11 A, 6. sek's 02241 Espoo Finland Tel. +358 9-863 40 520

Nordic Pharma

Nordic Pharma - UK	Nordic Pharma - France
Abbey House 1650 Arlington Business Park Theale, Reading RG7 4SA United Kingdom Tel +44 118 929 8233 info@nordicpharma.co.uk	10, rue René Anjolvy 94250 Gentilly France Tel. +33 1 72 46 72 00 info@nordicpharma.com

Nordic Pharma - Czech Republic

Nordic Pharma - The Netherlands

Nad Svahem 1766/6
140 000 Praha 4
Czech Republic

Tel +420 241 080 770
info@nordicpharma.cz

Tolweg 15
3741 LM Baarn
The Netherlands

Tel. +31 35 5480 580
Fax : +31 35 5480 589
info@nordicpharma.nl

Nordic Pharma - Belgium	Nordic Pharma - Poland
Garden Square C Laarstraat 16 2610 Wilrijk Belgium Tel. +32 3 820 52 24 info@nordicpharma.be	ul. Raclawicka 133 m.9 02-117 Warszawa Poland Tel/Fax. +48 601 991 119 info@nordicpharma.cz

Nordic Pharma - Germany

Nordic Pharma - Italy

Fraunhoferstr.4
85737 Ismaning
Germany

Tel. +49 89 889 690 680
E-mail. info@nordicpharma.de

Via Senigallia 18/2
20161 Milano
Italy

Tel. +39 02 6467 2810 / 2811
Fax : +39 02 6467 2400
E-mail. info@nordicpharma.it

Pharmaceutical Services

Prague Clinical Services - Czech Republic	QPharma - Sweden
Zachova 8 140 00 Praha 4 The Czech Republic Tel. +420 241 029 551 Fax. + 420 241 442 852 info@pragclin.com	Agneslundsvägen 27 201 25 Malmö Sweden Tel. +46 40 36 18 00 Fax. + 46 40 18 28 55 info@qpharma.se

Disphar International - The Netherlands
Tolweg 15 3741 LM Baarn The Netherlands Tel. +31 35 5280 400 Fax. +31 35 5480 585

Hyalobarrier®

Amélie — 2008-01-22T13:34:00Z

On January 22, 2008, the Nordic Group was granted the exclusive marketing and distribution rights to Hyalobarrier(r) for a number of European countries by Fidia Advanced Biopolymers.

Hyalobarrier(r) gel is the highly advanced bio-technology specialty product used for the prevention of post-surgical adhesions in abdominopelvic surgery.

Adhesions are internal scars : strand-like fibrous tissue that forms abnormal bonds between two parts of the body. After abdominal or pelvic surgery, adhesions can lead to severe clinical complications, such as bowel obstruction, infertility, and chronic abdominal or pelvic pain. There is a significant unmet medical need for the prevention of adhesions and their potential complications.

Hyalobarrier(r) is composed of an aqueous gel of ACP200(r), an original auto-cross-linked ester of hyaluronic acid, and the product is an highly effective barrier for protecting and separating tissues after abdominopelvic surgery. Given its physical characteristics, Hyalobarrier(r) perfectly adheres to the tissue surface and to the abdominal wall, and is easy to manipulate during laparotomic, laparoscopic and hysteroscopic procedures. The product completely degrades within 7 days by following the natural pathway of hyaluronic acid

The Nordic Group will commercialize Hyalobarrier(r) in France, United Kingdom, Ireland, the Benelux, Denmark, Sweden, Norway, Finland, Iceland, Czech & Slovak Republics, Poland, Bulgaria and in Germany, and intends to launch the product in the second half of 2008.

Indeus Life Sciences

inouit — 2007-11-12T18:24:16Z

INDEUS Life Sciences is a recently-established, Mumbay-based pharmaceutical development laboratory providing complete and high-quality formulation development services in full compliance with international standards and regulations, and in particular with those in the EU and the USA. The company’s services include the following :

Formulation development
Process validation
Analytical method development and validation
Technology transfer services
Stability studies as per ICH guidelines

The experienced management of INDEUS has extensive knowledge in product development for the US and EU markets.

INDEUS Life Sciences
SU Motor's Complex
Balrajeshwar Road
Model Town, Mulund (W),

Mumbai
Maharashtra 400 080, INDIA
Tel. +91-22-4161-1123
Fax. +91-22-2591-6792
Email. indeus@indeus.in

Siklos®

inouit — 2007-11-09T11:41:00Z

On November 9, 2007, the Nordic Group signed an agreement with Addmedica, through which Nordic was granted the exclusive marketing and distribution rights for Siklos® (hydroxycarbamide) in the UK and Ireland with the possibility of extending these rights to other EU countries.

On June 29, 2007, Addmedica obtained an EU Marketing Authorisation for Siklos® as an orphan product in the prevention of recurrent, painful vaso-occlusive crises, including Acute Chest Syndrome in paediatric and adult patients suffering from symptomatic Sickle Cell Syndrome.

Sickle Cell Syndrome is a group of inherited diseases caused by a gene mutation. This mutation leads to changes in haemoglobin. These changes bring about the abnormal shape and behaviour seen in Sickle Cell Syndrome patients' red blood cells, which become hard, sticky and shaped like a sickle. This shape causes blockages that slow blood flow, jeopardize the oxygenation of body tissue, and induce repeated, severe painful episodes, called vaso-occlusive crises, which require hospital admissions. In the long run, this causes severe damage to the organs. The clinical profiles of patients with Sickle Cell Syndrome can be remarkably varied. Sickle Cell Anaemia is the most common and severe disease.

Sickle Cell Syndrome affects 22 000 patients in Europe. Until now, no medicine has ever been registered for the treatment of Sickle Cell Syndrome in Europe.

Business Development

inouit — 2007-10-23T10:45:58Z

Through its in-house product development team, the Nordic Group strives towards developing proprietary products. However, the Nordic Group has always maintained a tradition of developing successful partnerships with third parties in addition to its own development projects.

Nordic Corporate Business Development actively seeks collaborations with companies that have similar high standards and interests in its core therapeutic areas and who are looking for a reliable partner with strong experience in accessing markets to promote and distribute their products in Europe

The Nordic Group also offers US, Japanese and other non-European companies the opportunity to take advantage of Nordic’s knowledge of the European markets and forge broad partnerships to develop, register and commercialise their products in Europe.

The Nordic Group’s therapeutic focus areas include :

Critical Care/Surgery
Oncology
Haematology
Rheumatology/Pain management
Gastroenterology
Gynaecology/Endocrinology

For all business development-related matters, please contact :

Stéphane Altaba, PhD
Director Corporate Business Development, Nordic Group
216 Boulevard St. Germain
75007 Paris
France
Tel. +33 1 53 63 88 77
Fax. +33 1 45 48 76 50
business.development@nordicpharma.com

Our vision

inouit — 2007-10-23T09:06:28Z

…To establish a pan-European speciality pharmaceutical group and to provide the highest quality international pharmaceutical products and services to our customers, partners and patients…

Our teams intend to continue developing the Nordic Group as a fully-integrated Pharmaceutical group with a strong European presence by respecting a number of core values and principles :

apply the highest ethical standards to our business conduct,
make our first responsibility our patients, their families, physicians, nurses and all other customers and stakeholders who use our products and services,
be responsible to our employees throughout the world,
be good citizens in the communities in which we live and work.

The Nordic vision includes offering its internal competencies and resources to third parties both as reliable services and as tools for building strategic partnerships. The various pharmaceutical service companies in the Nordic Group anticipate that their clients are entitled to expect a number of significant benefits by collaborating with Nordic, in particular in terms of speed, talent, reliability, efficiency, resources, excellence and IPR protection. Management and staff in the Nordic Group companies are fully committed to fulfilling these expectations.